186 related articles for article (PubMed ID: 33220353)
1. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis.
Carter MC; Maric I; Brittain EH; Bai Y; Lumbard K; Bolan H; Cantave D; Scott LM; Metcalfe DD
J Allergy Clin Immunol; 2021 Mar; 147(3):1004-1010.e2. PubMed ID: 33220353
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
3. Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series.
Kaminsky LW; Aukstuolis K; Petroni DH; Al-Shaikhly T
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):481-487. PubMed ID: 34175498
[TBL] [Abstract][Full Text] [Related]
4. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).
Distler M; Maul JT; Steiner UC; Jandus P; Kolios AGA; Murer C; Graf N; Seebach JD; Pichler WJ; Navarini AA; French LE; Helbling A; Schmid-Grendelmeier P
Dermatology; 2020; 236(6):529-539. PubMed ID: 31958790
[TBL] [Abstract][Full Text] [Related]
6. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
Chen M; Choo E; Yoo B; Raut P; Haselkorn T; Pazwash H; Holweg CTJ; Hudes G
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):666-673. PubMed ID: 33465457
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab.
Košnik M; Zugan L; Rijavec M
Int Arch Allergy Immunol; 2024 Mar; ():1-6. PubMed ID: 38527445
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.
Wood RA; Kim JS; Lindblad R; Nadeau K; Henning AK; Dawson P; Plaut M; Sampson HA
J Allergy Clin Immunol; 2016 Apr; 137(4):1103-1110.e11. PubMed ID: 26581915
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M
J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196
[TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab and hypersensitivity reactions.
Shankar T; Petrov AA
Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis.
Bilò MB; Corsi A; Brianzoni MF; Garritani MS; Antonicelli L
Ann Allergy Asthma Immunol; 2018 Aug; 121(2):249-250. PubMed ID: 29753833
[No Abstract] [Full Text] [Related]
13. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Kamide Y; Nakamura Y; Hamada Y; Tomita Y; Sekiya K; Tsuburai T; Izuhara K; Wakahara K; Hashimoto N; Hasegawa Y; Taniguchi M
Am J Respir Crit Care Med; 2020 Jun; 201(12):1488-1498. PubMed ID: 32142372
[No Abstract] [Full Text] [Related]
14. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab for hypersensitive reaction to seminal plasma: A case report.
Burguete-Cabanas MT; Fajardo-Ramirez OR; Yesaki R; Estrada-Maganas R; Salazar-Meza S; Rios-Chavez O; Meester I; Salas-Alanis JC
Allergol Int; 2018 Apr; 67(2):278-279. PubMed ID: 28821383
[No Abstract] [Full Text] [Related]
16. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
18. Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE.
Heymann PW; Platts-Mills TAE; Woodfolk JA; Borish L; Murphy DD; Carper HT; Conaway MR; Steinke JW; Muehling L; Gerald Teague W; Kennedy JL; Irani AM; McGraw MD; Early SV; Wheatley LM; Adams AP; Turner RB
J Allergy Clin Immunol; 2020 Sep; 146(3):545-554. PubMed ID: 32018030
[TBL] [Abstract][Full Text] [Related]
19. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
20. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis.
Giannetti MP; Weller E; Bormans C; Novak P; Hamilton MJ; Castells M
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):655-660. PubMed ID: 33465452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
